A propensity score-matched analysis comparing fracture risk associated with the initiation of SGLT2 inhibitors versus GLP-1RAs or DPP-4 inhibitors indicates use of SGLT2 inhibitors was not associated with an increase in risk of fractures in older patients with type 2 diabetes.
Take 5 minutes to catch up on Rheumatology Network's highlights from the week ending October 29, 2021.
Data show participants with early glucocorticoid use were more likely to be prescribed a biologic by 12 months, in comparison to non-users.
Cassandra Calabrese, DO, examines immunopathogenesis, immunomodulation, COVID-19 vaccinations, and pre-exposure prophylaxis.
Investigators called for the development of health care system structures to better support the exchanging of resources and information.
“Systemic lupus erythematosus is a chronic inflammatory autoimmune disease where a variety of organ complications contribute to an increased risk of premature mortality,” investigators stated.
Interview questions focused on mental and physical health, guidance received by healthcare providers, and the impact of COVID-19 on healthcare access and self-management behaviors.
“Using the strengthening exercises with mHealth may have the potential to reduce pain, improve mobility, functional activity, and activities of daily living among knee osteoarthritis patients who are overweight or obese," investigators stated.
Data show no significant improvement in pain, function and alignment scores over 26 weeks in the PRP injection group, compared to placebo.
Chronic back pain, a common symptom of axial spondyloarthritis that increases disease burden and reduces quality of life, may be improved by subcutaneous injection of secukinumab 150 mg or 300 mg.
The risk of adverse outcomes increased the most in pregnancies with antirheumatic treatment, especially those treated with biologic disease modifying antirheumatic drugs (bDMARDs), when compared with controls.
The rates of adverse events was similar across all 4 indications in comparison to the placebo group.
Take 5 minutes to catch up on Rheumatology Network's highlights from the week ending October 22, 2021.
A regular fitness routine was associated with less pain and stiffness, as well as an increase in functional capacity, in patients with knee osteoarthritis.
The study examines the impact of antirheumatic treatment on pregnancy outcomes in women with psoriatic arthritis.
A significant number of patients with psoriatic arthritis fail to achieve adequate disease control, resulting in health-related quality of life (HRQOL) impairments.
Dactylitis, a uniform swelling of an entire digit, occurs in up to half of patients with psoriatic arthritis and is sometimes the first manifestation of the condition.
Osteoporosis is a common comorbidity for patients with rheumatoid arthritis. How much do you know about how drugs impact bone health in rheumatoid arthritis?
“Evidence has accumulated on the effectiveness of physical activity to reduce disease-related symptoms such as pain and comorbidity risk in people with rheumatoid arthritis,” investigators stated.
Take 5 minutes to catch up on Rheumatology Network's highlights from the week ending October 15, 2021.
Approximately a third of systemic lupus erythematosus patients experience ocular involvement, which may be linked to disease pathophysiology.
Investigators analyzed the potential beneficial effect of hydroxychloroquine to prevent COVID-19 infection in patients with rheumatic disease.
“Considering medical appointments, laboratory tests, medications, and indirect costs, juvenile idiopathic arthritis generates elevated costs, which results in a high economic impact for the family,” investigators stated.
The post hoc analyses evaluated health-related quality of life and efficacy across 4 subgroups treated with either ixekizumab or adalimumab.
The Fast-Track Clinic reduced hospitalization rates for patients with polymyalgia rheumatica, which is helpful as symptoms of PMR can mimic other diseases, leading to hospitalization to rule out other conditions.
Upadacitinib achieved positive results from both Phase 3 SELECT-AXIS clinical trials, which focused on patients with ankylosing spondylitis and non-radiographic axial spondyloarthritis.
Take 5 minutes to catch up on Rheumatology Network's highlights from the week ending October 8, 2021.
The 2 studies focused on upadacitinib treatment for one group of patients with ankylosing spondylitis and another group of patients with non-radiographic axial spondyloarthritis.
An analysis of more than 1.2 million patients who experienced a fracture from 1997-2017 provides insight into contemporary trends in fracture incidence rates based on presence of diabetes.
Limited information is available on the overall disease burden of axial spondyloarthritis (axSpA) in women, as they are generally underrepresented in clinical studies.
